

Eye-Tech S.A.

Investor Presentation Sept 23, 2019





SAFE HARBOR STATEMENT



This presentation contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable securities legislation that involve risk and uncertainties. Such forward-looking statements or information may include financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. Actual results, performance, or developments could differ materially from those expressed or implied by the forward-looking statements contained in this presentation as a result of known and unknown risks,

All forward-looking statements made in this presentation are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.



WHAT WE DO

We provide Optical Coherence Tomography equipment to Hospitals, Scientific Institutions & Small Ophthalmology Clinics.



OUR IMAGING PRODUCTS



Advanced OCT Solutions



Basic OCT Solutions




MARKET OPPORTUNITY



The global markets for optical coherence tomography (OCT) should reach \$1.5 billion by 2023 from \$993.9 million in 2018 at a compound annual growth rate (CAGR) of 8.8% for the period of 2018 to 2023.

Europe - Eye-Tech main focus is second biggest market WW

Main competitors: Agfa Healthcare, Carl Zeiss Meditec AG, Heidelberg Engineering GmbH, Imalux Corporation, Michelson Diagnostics, OPTOPOL Technology S.A., Novacam Technologies Inc., Thorlabs Inc., Topcon Medical Systems Inc. and Agiltron Inc.






RECURRING / REPEATABLE REVENUE GROWTH



Recurring revenue contribution forecast to grow to \$4.1M in FY19






FY18 FINANCIAL HIGHLIGHTS (USD)



- Gross Margin of 61% up from 56% in prior year
- Revenue \$14.2M an increase of 12% over FY17
- EBITDA \$99k
- EBITDA \$1.1M FY2019 (as at June 30, 2019)





GROWTH OPPORTUNITIES



- Continued market penetration and introduction of value-added DaaS model
- Expansion of Software Maintenance & Support program within current customer base
- AI and data opportunities related to hosted image data lake for deep machine learning and data analytics
- International expansion





CAPITALIZATION AND SHARE INFORMATION



Exchange Listings:



Tick: EYETECH

	Basic Shares O/S	As-converted basis for Pref. Shares
Current Capitalization		
Share Price (C\$) <small>(Sept 19 / 20/19 closing)</small>	\$0.42	\$0.42
Common Shares O/S (mm)	38.8	59.1
Market Capitalization (C\$ mm)	\$16.2	\$24.82
Equity Capital Structure	(mm)	(mm)
Common Shares O/S	38.8	59.1
Convertible Preferred Shares	20.3	-
<u>Dilutive Securities:</u>		
Options	3.70	3.70
Warrants	0.69	0.69
Fully-Diluted Shares	63.49	63.49
Selected Balance Sheet Items	(US\$ mm)	(US\$ mm)
Cash	\$2.77	\$2.83
Debt	\$1.86	\$1.86
Conv. Pref. Share Obligations	\$6.35	-

As at Sept 19, 2019


CAPITALIZATION AND SHARE INFORMATION CONTINUED

Trailing 12-month Price and Volume



Ownership Summary

Basic Shares O/S



Fully-diluted (Prefs. Converted)



Investor Relations Contact: Tomasz Klekowski

t.klekowski@eye-tech.com